Can policy interventions meaningfully change the effects of AI mental health chatbots?

What are the main risks that policy can actually fix?

Policy interventions are most effective where the problem is clear, measurable, and caused by a lack of rules—exactly the situation with safety failures, privacy breaches, and accountability gaps in AI mental health chatbots. A 2025 scoping review of 101 articles found that privacy and confidentiality were the most frequently discussed ethical concern, appearing in 61.4% of papers, followed by safety and harm (51.5%), which includes failures to handle suicidal crises and giving harmful advice [1]. These are not hypothetical: a 2023 field study of actual user conversations with companion AIs found that mental health crises were present in a non-negligible minority of interactions, and the chatbots were often unable to recognize or respond appropriately to signs of distress [3]. Policy can mandate that chatbots have clear crisis escalation protocols, require transparency about the AI's limitations (the 'black box' problem flagged in 25.7% of articles [1]), and assign legal responsibility when the AI causes harm—a 'responsibility vacuum' that current regulations leave open [2].

User feedback from thousands of reviews of Woebot and Wysa confirms that privacy concerns and lack of trust are major barriers to adoption [4]. Policies that enforce data protection standards and require plain-language explanations of how user data is used directly target these barriers. The same study notes that policy discussions are already underway to support insurance reimbursement for AI mental health tools, which would address the 'price value' barrier that users identified [4]. So on the risk-mitigation side, the evidence is consistent across multiple studies: policy can meaningfully reduce documented harms.

Can policy make chatbots actually improve mental health outcomes?

Here the evidence is much weaker and more mixed. A 2024 scoping review of 10 studies on AI chatbots for anxiety, stress, and depression found 'some promising effects' but noted that the overall quality of the evidence was lower than expected, many studies used rudimentary versions of the technology, and undesirable effects were poorly described [5]. In other words, we don't yet have high-quality proof that chatbots reliably improve symptoms, so no policy can mandate effectiveness that hasn't been demonstrated.

User reviews add another layer of caution: even among generally positive sentiment, users consistently complained about generic responses, emotional disconnect, and the chatbot's inability to handle complex or nuanced conversations [4]. These are design and capability limitations, not regulatory gaps. A 2026 analysis of the 'therapeutic misconception'—the risk that users overestimate the chatbot's ability to help—argues that policy should focus on informed consent and clear communication of the chatbot's limitations, rather than pretending regulation can make the AI a therapist [2]. So while policy can ensure users are not misled, it cannot force a chatbot to develop genuine empathy or clinical judgment. The 2025 ethics review explicitly calls for more research comparing the risks and benefits of AI versus human therapists before we can know what 'good enough' looks like [1].

In short, policy is a powerful tool for harm reduction but a weak tool for outcome improvement. The two are often conflated, but the evidence separates them clearly.

Where do the studies agree, and where do they conflict?

There is strong agreement across all five papers on two points: (1) privacy and safety are the most urgent and well-documented risks, and (2) the current evidence base for effectiveness is too weak to support strong claims. The 2025 ethics review [1], the 2023 field study [3], and the 2026 user feedback analysis [4] all converge on the same set of core concerns—crisis mismanagement, data privacy, and lack of transparency—using different methods (literature review, direct observation of conversations, and user reviews), which strengthens the conclusion that these are real, not just theoretical, problems.

The main conflict is about how much weight to give user satisfaction versus clinical outcomes. The user feedback study [4] reports overall positive sentiment toward Woebot and Wysa, while the field study [3] found that companion AIs frequently failed to respond appropriately to distress. These are not contradictory—users can feel helped even when the chatbot is clinically inadequate—but they highlight a tension: policy that focuses only on user satisfaction could miss serious safety gaps. The 2024 review [5] and the 2026 legal analysis [2] both caution that the technology is evolving faster than the evidence, and that policy must be adaptive rather than rigid. No study claims that policy is irrelevant; rather, they agree that policy is necessary but insufficient on its own.

About These Sources

This answer is built on 5 peer-reviewed studies — published from 2023 to 2026, 4 from 2024 or later, 2 in Q1 journals, collectively cited 181 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 41 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions